Dr. Michele Ramien talks with JCMS editor-in-chief Dr. Kirk Barber about the article she co-authored in the Nov-Dec 2019 issue of the Journal of Cutaneous Medicine and Surgery. In their conversation, Michele describes to Kirk the potential efficacy of cyclosporine A in the treatment of Mycoplasma pneumoniae-induced rash and mucositis, also known as MIRM. MIRM is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin.Dr Ramien is a clinical associate professor of dermatology and community pediatrics at the University of Calgary. She is also vice chair of the Camp Liberté Society, a camp for children with skin disorders.Music is by Lee Rosevere.JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa.davidrcmcguffin@gmail.com